🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Recruiting
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479Myeloid Leukemia, Philadelphia Positive
Novartis Pharmaceuticals
Phase 1/2
34
Hangzhou, Beijing, Shanghai, Tianjin
2021-12-27
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan
2021-12-20
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
Merck Sharp & Dohme LLC
Phase 1
830
Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou
2021-12-17
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
Recruiting
China National Registry of Neuro-Inflammatory Diseases
NCT05154370Multiple Sclerosis, NMO Spectrum Disorder, Clinically Isolated Syndrome, CNS Demyelinating Autoimmune Diseases
Beijing Tiantan Hospital
Observational
10,000
Beijing
2021-12-15
Active, closed
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859Hepatitis B
GlaxoSmithKline
Phase 2
360
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Liuzhou
2021-12-14
Active, closed
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858Generalized Myasthenia Gravis
Regeneron Pharmaceuticals
Phase 3
288
Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha
2021-12-14
Active, closed
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
NCT05022654Esophageal Squamous Cell Carcinomas
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
22
Beijing, Anyang, Luoyang, Xuzhou, Taiyuan, Suining
2021-12-13
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,007
Wuhan, Nanjing, Yinchuan, Taiyuan, Hangzhou, Wenzhou, Beijing, Shanghai
2021-12-13
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou
2021-12-13
Recruiting
Corheart 6: Long-term Cohort Study
NCT07094919Heart Failure
China National Center for Cardiovascular Diseases
Not applicable
160
Shenzhen, Zhengzhou, Wuhan, Nanjing, Beijing, Shanghai
2021-12-12
Recruiting
Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer
NCT05202314Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction
Beijing Chao Yang Hospital
Not applicable
20
Beijing
2021-12-12
Recruiting
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer
NCT05751018Non-small Cell Lung Cancer
Peking Union Medical College Hospital
Phase 2
18
Beijing
2021-12-08
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
Long-term Efficacy and Safety Study of GV-971
NCT05181475Alzheimer Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
800
Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Shenzhen, Guiyang, Baoding
2021-12-07
Active, closed
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT05002777Warm Autoimmune Hemolytic Anemia (wAIHA)
Sanofi
Phase 2
22
Beijing, Tianjin
2021-12-07
Recruiting
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
NCT05072600Bladder Cancer, Bladder Neoplasms, Bladder Tumors, Urinary Bladder Cancer
Peking University First Hospital
Phase 2
54
Beijing
2021-12-07
Recruiting
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
NCT04996121Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1/2
360
Beijing
2021-12-06
Active, closed
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
NCT04950322Gastric or Gastroesophageal Junction Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
737
Beijing
2021-12-06
Active, closed
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
Jazz Pharmaceuticals
Phase 3
920
Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou
2021-12-02
Recruiting
Clinical Pharmacology of Dexamethasone in Pregnant Women With Preterm Labor
NCT05207852Respiratory Distress Syndrome of Newborn, Threatened Premature Labor, Antepartum
Dongyang Liu
Observational
288
Beijing
2021-12-01
Active, closed
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NCT05112965Neoplasms
Hoffmann-La Roche
Phase 3
49
Guangzhou, Harbin, Wuhan, Jinan, Hangzhou, Beijing, Changchun, Changsha
2021-12-01
Recruiting
Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China
NCT06655090Interstitial Lung Disease (ILD)
Dai Huaping
Observational
10,000
Beijing
2021-12-01
Active, closed
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
NCT05245968Gastrointestinal Stromal Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1
78
Beijing, Shanghai
2021-12-01
Recruiting
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
NCT05088226Peripheral Blood Stem Cell Transplantation
Chinese PLA General Hospital
Phase 2
50
Beijing
2021-12-01
Not yet open
Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)
NCT05105321Metabolic Syndrome
Tang Yida
Phase 4
5,200
Beijing
2021-12
Active, closed
The Study on the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System
NCT06660927Common Iliac Artery Aneurysm
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
500
Beijing
2021-11-30
Recruiting
OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding
NCT04902248Upper Gastrointestinal Bleeding
Chinese University of Hong Kong
Not applicable
236
Beijing, Nanchang, Chengdu
2021-11-27
Active, closed
Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis
NCT07044115Lupus Nephritis
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
41
Beijing
2021-11-26
Recruiting
Multicomponent Prehabilitation and Outcomes in Elderly Patients With Frailty
NCT04715581Old Age; Debility, Digestive Cancer, Surgery, Preoperative Rehabilitation
Peking University First Hospital
Not applicable
540
Beijing
2021-11-25
Recruiting
The Impact of Immune Cell Changes During the Perioperative Period on the Prognosis of Patients With Colorectal Cancer
NCT05015296Colorectal Cancer
Beijing Friendship Hospital
Observational
7,000
Beijing
2021-11-23
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
17,004
Beijing, Foshan, Guangzhou, Nanning, Harbin, Jingzhou, Wuhan, Changsha
2021-11-23
Active, closed
TACS Intervention for Methamphetamine Addiction
NCT06288997Methamphetamine Use Disorder
Shanghai Mental Health Center
Not applicable
70
Beijing, Wuhan, Nanjing, Suzhou, Deyang
2021-11-21
Active, closed
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
NCT06391944Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation
Shanghai JMT-Bio Inc.
Phase 2
161
Beijing
2021-11-21
Active, closed
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)
AstraZeneca
Phase 3
145
Beijing, Guangzhou, Shenyang
2021-11-19
Recruiting
Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)
NCT05559645Non Small Cell Lung Cancer
Peking Union Medical College Hospital
Not applicable
180
Beijing
2021-11-18
Active, closed
Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921Muscular Atrophy, Spinal
Biogen
Observational
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2021-11-18
Recruiting
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
NCT05121779Pulmonary Fibrosis
Peking Union Medical College Hospital
Phase 1
80
Beijing
2021-11-18
Recruiting
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
NCT05145127Hemophilia A, Hemophilia B
Pfizer
Phase 3
245
Guangzhou, Guiyang, Wuhan, Nanchang, Tianjin, Beijing
2021-11-17
Active, closed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04958265Atypical Hemolytic Uremic Syndrome
Hoffmann-La Roche
Phase 3
41
Beijing, Hangzhou
2021-11-17
Active, closed
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925Primary Immune Thrombocytopenia
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Active, closed
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer
NCT05077449Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3
300
Beijing
2021-11-16
Active, closed
A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
NCT05210868Hematoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
184
Beijing
2021-11-16
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Recruiting
Safety and Efficacy of a Multi-branched Thoracoabdominal Stent Graft System for Thoracoabdominal Aortic Aneurysm.
NCT05054985Thoracoabdominal Aortic Aneurysms
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
73
Beijing
2021-11-12
Active, closed
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
NCT04684108Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
61
Bengbu, Beijing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Xiangyang, Wuxi
2021-11-04
Recruiting
Comparison of MBR + Suture Tape, MBR, and Anatomic Reconstruction for CLAI in GJL Cases: A Prospective Cohort Study
NCT05698446Ankle Sprains, Hypermobility Syndrome
Peking University Third Hospital
Observational
114
Beijing
2021-11-01
Active, closed
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
NCT05013190Multiple Myeloma
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
454
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan
2021-10-28
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Recruiting
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
NCT07392736Solid Tumor
Advenchen Laboratories, LLC
Phase 1/2
228
Beijing, Hunan, Fuzhou, Shantou, Shaoguan, Guilin, Liuzhou, Nanning
2021-10-26
Recruiting
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT05104788Non-Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2
27
Beijing
2021-10-25
Recruiting
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Bayer
Phase 1/2
400
Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan
2021-10-25
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Active, closed
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT04861259Atypical Hemolytic Uremic Syndrome
Hoffmann-La Roche
Phase 3
83
Beijing
2021-10-22
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
AstraZeneca
Phase 1/2
460
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
2021-10-18
Active, closed
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT05104866Breast Cancer
AstraZeneca
Phase 3
732
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou
2021-10-18
Active, closed
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
587
Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2021-10-14
Active, closed
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1
45
Beijing, Guangzhou, Nanjing, Tianjin, Hangzhou
2021-10-13
Active, closed
Study of Sacituzumab Govitecan in Patients With Solid Tumor
NCT05119907Solid Tumor
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Recruiting
Prospective Study on Quality of Life in Patients With Intracranial Germ Cell Tumors
NCT05124964Quality of Life
Beijing Tiantan Hospital
Observational
150
Beijing
2021-10-12
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Active, closed
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922Ovarian Cancer, Recurrent Cancer
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Active, closed
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
NCT05485948Polycythemia Vera
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Recruiting
Thoracoabdominal Aortic Stent System for Endovascular Treatment of Thoracoabdominal Aortic Dissecting Aneurysm.
NCT05803564Thoracoabdominal; Aortic, Aneurysm, Dissecting
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
46
Beijing
2021-10-01
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca
Phase 1/2
136
Beijing, Guangzhou
2021-09-28
Recruiting
First in Human, Dose Escalation Study of AN4005
NCT04999384Advanced Solid Tumor, Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.
Phase 1
31
Beijing, Harbin, Wuhan
2021-09-27
Recruiting
China Kidney Patient Trials Network
NCT05036850Kidney Diseases
George (Beijing) Clinical Research Co. Ltd.
Observational
1,200
Beijing
2021-09-27
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
309
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Hohhot, Nanchang, Shenyany
2021-09-23
Active, closed
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136Primary Biliary Cholangitis, PBC
Mirum Pharmaceuticals, Inc.
Phase 2
333
Fuzhou, Wuhan, Changchun, Hangzhou, Beijing
2021-09-22
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
600
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang
2021-09-20
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan
2021-09-20
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605Relapsed/Refractory Multiple Myeloma
BeOne Medicines
Phase 1/2
246
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2021-09-16
Recruiting
The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors
NCT05124951Intracranial Germ Cell CNS Tumor, Childhood
Beijing Tiantan Hospital
Phase 2
150
Beijing
2021-09-15
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche
Phase 1/2
42
Beijing, Shanghai
2021-09-14
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
BeOne Medicines
Phase 1/2
645
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT04765059Non-small Cell Lung Cancer
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Recruiting
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
NCT05424692Colon Cancer, Rectal Cancer, Chemotherapy Effect, PTC
Peking Union Medical College Hospital
Not applicable
200
Beijing
2021-09-01
Recruiting
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
NCT05069220Neuroendocrine Tumor, Neuroblastoma, Pheochromocytoma, Paraganglioma
Peking Union Medical College Hospital
Phase EARLY_PHASE1
150
Beijing
2021-09-01
Recruiting
Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
NCT05498675Sacubitril/Valsartan, Hypertension, Obesity
Beijing Friendship Hospital
Observational
180
Beijing
2021-09-01
Recruiting
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
NCT05647109Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia
Peking University People's Hospital
Observational
244
Beijing
2021-09-01
Active, closed
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811Non Small Cell Lung Cancer
Nuvation Bio Inc.
Phase 2
217
Beijing, Zhengzhou, Shanghai, Changsha, Chengdu, Jinan, Wuhan
2021-09-01
Recruiting
Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)
NCT06353334Butylphthalide, Cardiac Arrest, Neuroprotective Drugs
Tang Ziren
Phase 4
100
Beijing
2021-09-01
Not yet open
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
NCT04995159Coronary Heart Disease
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
2,150
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Foshan, Guangzhou
2021-09
Recruiting
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
NCT05316805Atopic Dermatitis Eczema, Prurigo Nodularis
Peking University First Hospital
Observational
100,000
Beijing
2021-08-31
Active, closed
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
NCT04957550Psoriatic Arthritis
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
418
Beijing
2021-08-30
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
Hoffmann-La Roche
Phase 3
4,170
Zhengzhou, Changsha, Nanchang, Changchun, Shanghai, Chengdu, Hangzhou, Beijing
2021-08-27
Recruiting
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
NCT05372263Pulmonary Hypertension
China National Center for Cardiovascular Diseases
Observational
700
Beijing
2021-08-26
Recruiting
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
NCT04982276Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 1/2
138
Beijing
2021-08-23
Active, closed
Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases
NCT06611657Whole Brain Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2021-08-20
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning
2021-08-19
Active, closed
Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament
NCT04968028Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy
Shanghai Changzheng Hospital
Not applicable
167
Beijing, Shenzhen, Harbin, Jining, Qingdao, Shanghai, Taiyuan, Xi’an
2021-08-17
By invitation
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
NCT04957719Acute Myocardial Infarction
Viatris Innovation GmbH
Phase 3
25,000
Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-08-14
Rows per page Showing 4801–4900 of 5484
Previous 47 48 49 50 51 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=49

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.